Your browser doesn't support javascript.
loading
Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia.
Kan, Winnie L; Dhagat, Urmi; Kaufmann, Kerstin B; Hercus, Timothy R; Nero, Tracy L; Zeng, Andy G X; Toubia, John; Barry, Emma F; Broughton, Sophie E; Gomez, Guillermo A; Benard, Brooks A; Dottore, Mara; Cheung Tung Shing, Karen S; Boutzen, Héléna; Samaraweera, Saumya E; Simpson, Kaylene J; Jin, Liqing; Goodall, Gregory J; Begley, C Glenn; Thomas, Daniel; Ekert, Paul G; Tvorogov, Denis; D'Andrea, Richard J; Dick, John E; Parker, Michael W; Lopez, Angel F.
Afiliação
  • Kan WL; Cytokine Receptor Laboratory, Centre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, South Australia, Australia.
  • Dhagat U; Australian Cancer Research Foundation Rational Drug Discovery Centre, St. Vincent's Institute of Medical Research, Fitzroy, Victoria, Australia.
  • Kaufmann KB; Department of Biochemistry and Pharmacology and the Australian Cancer Research Foundation Facility for Innovative Cancer Drug Discovery, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, Victoria, Australia.
  • Hercus TR; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Nero TL; Cytokine Receptor Laboratory, Centre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, South Australia, Australia.
  • Zeng AGX; Australian Cancer Research Foundation Rational Drug Discovery Centre, St. Vincent's Institute of Medical Research, Fitzroy, Victoria, Australia.
  • Toubia J; Department of Biochemistry and Pharmacology and the Australian Cancer Research Foundation Facility for Innovative Cancer Drug Discovery, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, Victoria, Australia.
  • Barry EF; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Broughton SE; Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
  • Gomez GA; Centre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, South Australia, Australia.
  • Benard BA; Cytokine Receptor Laboratory, Centre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, South Australia, Australia.
  • Dottore M; Australian Cancer Research Foundation Rational Drug Discovery Centre, St. Vincent's Institute of Medical Research, Fitzroy, Victoria, Australia.
  • Cheung Tung Shing KS; Department of Biochemistry and Pharmacology and the Australian Cancer Research Foundation Facility for Innovative Cancer Drug Discovery, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, Victoria, Australia.
  • Boutzen H; Cytokine Receptor Laboratory, Centre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, South Australia, Australia.
  • Samaraweera SE; Division of Hematology, Department of Medicine, Cancer Institute, and Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California.
  • Simpson KJ; Cytokine Receptor Laboratory, Centre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, South Australia, Australia.
  • Jin L; Australian Cancer Research Foundation Rational Drug Discovery Centre, St. Vincent's Institute of Medical Research, Fitzroy, Victoria, Australia.
  • Goodall GJ; Department of Biochemistry and Pharmacology and the Australian Cancer Research Foundation Facility for Innovative Cancer Drug Discovery, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, Victoria, Australia.
  • Begley CG; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Thomas D; Centre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, South Australia, Australia.
  • Ekert PG; Victorian Centre for Functional Genomics, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Tvorogov D; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.
  • D'Andrea RJ; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Dick JE; Centre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, South Australia, Australia.
  • Parker MW; Department of Medicine, University of Adelaide, Adelaide, South Australia, Australia.
  • Lopez AF; Begley Biotech Consulting, Wallington, Victoria, Australia.
Cancer Discov ; 13(8): 1922-1947, 2023 08 04.
Article em En | MEDLINE | ID: mdl-37191437
Leukemia stem cells (LSC) possess distinct self-renewal and arrested differentiation properties that are responsible for disease emergence, therapy failure, and recurrence in acute myeloid leukemia (AML). Despite AML displaying extensive biological and clinical heterogeneity, LSC with high interleukin-3 receptor (IL3R) levels are a constant yet puzzling feature, as this receptor lacks tyrosine kinase activity. Here, we show that the heterodimeric IL3Rα/ßc receptor assembles into hexamers and dodecamers through a unique interface in the 3D structure, where high IL3Rα/ßc ratios bias hexamer formation. Importantly, receptor stoichiometry is clinically relevant as it varies across the individual cells in the AML hierarchy, in which high IL3Rα/ßc ratios in LSCs drive hexamer-mediated stemness programs and poor patient survival, while low ratios mediate differentiation. Our study establishes a new paradigm in which alternative cytokine receptor stoichiometries differentially regulate cell fate, a signaling mechanism that may be generalizable to other transformed cellular hierarchies and of potential therapeutic significance. SIGNIFICANCE: Stemness is a hallmark of many cancers and is largely responsible for disease emergence, progression, and relapse. Our finding that clinically significant stemness programs in AML are directly regulated by different stoichiometries of cytokine receptors represents a hitherto unexplained mechanism underlying cell-fate decisions in cancer stem cell hierarchies. This article is highlighted in the In This Issue feature, p. 1749.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Receptores de Citocinas Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Cancer Discov Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Austrália

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Receptores de Citocinas Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Cancer Discov Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Austrália